| dc.description.abstract | Benign prostatic hyperplasia (BPH) is a clinical syndrome include an enlarged prostate and lower urinary tract symptoms (LUTS). Pharmacological BPH treatment protocols recommend using alpha-blockers and 5α-reductase inhibitors (5ARI), monotherapy or in combination, along with phosphodiesterase-5 (PDE5) inhibitor, individually or in combination with alpha-blockers. Management of sexual dysfunction in men treated with BPH/LUTS must be focused and dependent on symptoms. Validated investigative questionnaires, such as the international index of erectile function or the male sexual health questionnaire, should be used to assess sexual function before starting pharmacological therapy for BPH/LUTS. Methods: This study used a descriptive research type with a retrospective cohort design at the Adam Malik Haji Center General Hospital in Medan and the University of North Sumatra Hospital, using all BPH patients from January 2016 to December 2021. The sample of this study met the inclusion and exclusion criteria. The data obtained by searching medical record data. Results: The distribution of the frequency of respondents based on age showed that the average age of the respondents was 69.21+9.236 years (43-75 years), where the total number of patients were male was 86 people (100%). Based on IIEF-5 showed those mild-moderate prostate symptoms had as many as 56 people (65.1%) respondents; in the moderate category were 24 people (27.9%), and in the mild categories were 6 people (7%). The average respondent, as a whole, has an IIEF-5 score of 13.52+2.467 (10-18). Conclusion: This study shows that respondents with BPH based on IIEF-5 have mild-moderate symptom stages more than other symptom stages. | en_US |
